SFEBES2025 Poster Presentations Adrenal and Cardiovascular (61 abstracts)
An annual mortality rate of 42% is noted in profound hyponatraemia (Na <120 mmol/l) patients
Arjun Raj 1 , Haider Abbas 1 , Malgorzata Lubczynska 1 , Terry Lebutt 1 , Emma Bremner 1 , Amy Morrison 1,2 , Faizanur Rahman 1 , Shailesh Gohil 1,2 , Miles Levy 1,2 & Narendra Reddy 1,2
1University Hospitals of Leicester NHS Trust, Leicester, United Kingdom; 2University of Leicester, Leicester, United Kingdom
Background: Profound hyponatraemia is associated with considerable morbidity and mortality. There is a lack of mortality rate estimation in severe hyponatraemia patients.
Objective: We explore calculating mortality rates in patients admitted with severe hyponatraemia of Serum sodium (Na) <120 mmol/l.
Methodology: Retrospective case notes & electronic records’ review were undertaken to identify hyponatraemia patients admitted to University Hospitals of Leicester (UHL) from 1st January 2022 to 31st December 2022 (UHL QIP No:11408). All consecutive patients of Na <120 were identified based on UHL lab & electronic mortality records.
Results: n = 622 patients with a Na <120 mmol/L included; mean Na=115 mmol/l. Total deaths= 329 occurred as of 16th October 2024. 260/622 (42%) of profound hyponatraemia patients died within a year of Na<120 reading. Out of 329 deaths, 79/329 (24%) of deaths occurred within 7 days, 131/329 (40%) deaths occurred within 30 days & 260/329 (79%) deaths occurred within 365 days. Mean= 173 days, the duration from time of least Na value to death; Median= 55 days.
Discussion: The degree of hyponatraemia is a marker of severity of the underlying aetiology. In our study, 1 in 5 hyponatraemia patients (21%) died within a month of Na<120 & 2 in 5 (42%) died within a year. In comparison, pancreatic cancer has a 1-year mortality rate of 74%. Further explorative analysis of non-cancer mortality rates & various aetiologies are currently being undertaken.
Learning points: 1. Profound hyponatraemia patients with Na <120 mmol/L have very poor prognosis with an estimated mortality of >40% at 1 year irrespective of the aetiology.2. Aggressive management is imperative to identify the underlying aetiology and appropriate treatment strategies placed.3. To educate patients & families about the poor prognosis in such cohort of patients if irreversible causes are identified such as malignancy, end-stage organ failure etc.
Volume 109
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more